Skip to content
Screener

Halozyme Therapeutics HALO Contract Liabilities

Contract Liabilities at other companies

West Pharmaceutical Services logo
West Pharmaceutical ServicesWST
$45.7M-1.1%
AptarGroup logo
AptarGroupATR
$47.84M+3.1%
Aquestive Therapeutics, Inc. logo
Aquestive Therapeutics, Inc.AQST
$19.12M-3.2%
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$63.03M-49.6%
Arrowhead Research logo
Arrowhead ResearchARWR
$48.62M—
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$11.78M—

Other financials

Income statement

See full
Revenue$481.0M+47.7%
Gross profit$401.8M+43.8%
Operating income$287.7M+42.1%
Net income$229.9M+39.2%
EPS (diluted)$1.90+42.9%

Balance sheet

See full
Cash & equivalents$164.0M+165%
Total debt$2.2B+41.6%
Total equity$143.5M-56.9%
Total assets$2.6B+25.5%

Cash flow

See full
Operating cash flow$240.9M+142%
CapEx$4.2M+167%
Free cash flow$236.7M+141%

Valuation

See full
Market cap$9.91B+36.0%
Enterprise value$11.93B+36.1%
P/E13.8×-3.9×
P/S6×-0.2×

Profitability

See full
Gross margin82.4%-1.8pp
Operating margin59.3%+9.0pp
Net margin47.9%+6.5pp
FCF margin48.5%+2.6pp

Returns & leverage

See full
Return on equity124.5%+12.7pp
Debt / equity15.2×+10.6×
Current ratio2.7×-5.7×

Where this comes from

Reported directly by Halozyme Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:ContractWithCustomerLiability.

The source filing: Halozyme Therapeutics’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:11 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001159036-26-000104
Line itemJune 30, 2026December 31, 2025
Accounts receivable, net$453,327$426,273
Other contract assets2,50015,000
Deferred revenues31,66935,482

Item 1. Financial Statements

FAQ

What is Halozyme Therapeutics's contract liabilities?
Halozyme Therapeutics (HALO) reported contract liabilities of $31.67M in Q2 2026.
How has Halozyme Therapeutics's contract liabilities changed year-over-year?
Halozyme Therapeutics's contract liabilities increased by 278.2% year-over-year, from $8.37M to $31.67M.
What is the long-term trend for Halozyme Therapeutics's contract liabilities?
Over 5 years (2020 to 2025), Halozyme Therapeutics's contract liabilities has grown at a 54.5% compound annual growth rate (CAGR), from $4.03M to $35.48M.
What does contract liabilities mean?
Revenue collected or billed in advance of performance — deferred revenue under ASC 606 terminology, representing future revenue obligations.

Ask your AI about Halozyme Therapeutics's contract liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude